Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial
One tablet should be taken with the and one with the evening meal to ensure proper absorption. Target Population :
Stop other Class I or III antiarrhythmics (e.g., amiodarone, sotalol) before starting Multaq. Avoid strong (e.g., ketoconazole). ATHENA HEART [310]
: Classified as Category X ; it may cause fetal harm and should not be used by pregnant women. Drug Interactions :
The official FDA label outlines critical safety measures based on ATHENA data: : Based on the code , this guide provides
Following the ATHENA results, dronedarone was approved with specific administration and safety protocols. : The only recommended dose is 400 mg twice daily .
: Do not use in patients who cannot or will not be converted to sinus rhythm. Target Population : Stop other Class I or
: To determine if dronedarone could lower the risk of hospitalization due to cardiovascular events or death from any cause in patients with atrial fibrillation (AF) or atrial flutter (AFL).